NCT03414788View on ClinicalTrials.gov

Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 7, 2020

Primary Completion Date

February 1, 2022

Study Completion Date

February 1, 2022

Conditions
Inflammatory Bowel Disease
Interventions
BIOLOGICAL

PF 06687234

Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously

BIOLOGICAL

[124I]IB PF 06687234

Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03414788 - Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease | Biotech Hunter | Biotech Hunter